Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scotty it took you awhile to muster up this dis of the sp move today, which was about 30%. And stated with a straight face I’m sure. Me, I rather enjoyed the 14 cent gain today!
Perhaps Flintstone like action pedals can fold out of the floorboards for dead battery recharge
Almost the NJ state anthem and unofficially it probably is: Baby we were born to run!
I might be overestimating the importance of the flaskworks acquisition but strategically I’m guessing that the company and the IP may be valuable beyond dcvax to broader cellular treatments automated and non super clean room (lower cost) manufacturing!
Thank you for the details and tie in to Bio’s post!
Well said and I agree LP is a genius and maybe as important she is not a quitter and she is committed to getting to the goals.
FWIW I remember something about perhaps Germany was requiring too low a price for dcvax treatment and NWBO might not have wanted to set that precedent, thus forgoing that revenue opportunity. I don’t know if that was actually the case or just a theory.
We can get Tom Hanks to reprise his Davinci Code and Angels and Demons character for the movie
I’m a very patient person but the constant statements about NWBO not getting to DL are wearing me out.
What does it take to understand that the process at this point is not executed by NWBO but rather by the CRO, until the unblinded data is shared with NWBO. The PRs have detailed this out step by step.
Face the reality, DL is imminent and unblinding will happen and TLD should be in existence within September.
If NWBO takes more than 3 weeks from their unblinding to release top line results then I will join those crying foul, because that ball is in NWBO’s court.
Is that a promise?
As I understand approval looks beyond efficacy to the ability to manufacture the treatment consistently and in quantity.
LP taught classes on bringing new treatments to commercial availability. It’s in her bio and it’s an impressive bio.
Not just a backup at the same company, rather another source (company/vendor) so one isn’t subject to monopolistic pricing situations, etc.
More than two labs will probably arise such as how Germany was requiring Dcvax made in Germany. In my former business I had encountered EU and other non EU countries having requirements such as EU/country hosting of facilities, etc.
In any event, Anders, we are on the same (long) side and I was just responding to your question since I’m in nwbo around a decade and haven’t yet forgotten all the nwbo info I have picked up on this message board.
Peace
Doc stated the other big reason, that EU approval and use of Dcvax May mandate or strongly favor an EU vaccine making presence.
This raises a point, that nwbo is deeper and more sophisticated along multiple dimensions than the naysayers ever give them credit. Nwbo knows DC vaccine making variables and the science better than most, if not all, players in the field.
Yes, and you have to get the tumor tissue to the vaccine making facility as well as the blood draw.
In a pinch, if one of the 2 labs is down, and to have some dual sourcing possibility to avoid exploitation in a single source situation, it is good to have two viable manufacturers.
Years ago it was determined that it would be required to manufacture dcvax at cognate shipping out of Memphis to USA/Americas/Canada and an European manufacturing site for Europe/Eastern Hemisphere, hence winding up with the UK/Advent. It was driven by logistics not greed. The vaccine needs to remain frozen until it’s use.
More Rodney
“My wife will only have sex with me once a month, but that’s not bad, I know two guys she’s cut out altogether”
“My neighborhood’s so tough, they don’t shoot you, they insert the bullets manually”
Now that would be quite a contribution!
Anyone live near Duffy?
“Blue parrot likes a DC vaccine”
Seriously, thanks in advance! Just don’t get Bosch into a position that could sour the regulatory agencies at this late date in the trial and early in approval processes.
Yes, Dante’s Divine Comedy Inferno (Hell,) paraphrasing because I don’t remember exactly, “I don’t know how I came to be in this terrible place” - Something manipulating shorts might ponder?
Dante ?
Being serious now, the diversity of thoughts, beliefs, experiences, and knowledge, shared on this board is enlightening, educational, and compelling reading to me.
But then again I find opening the mail exciting
Geez flip I’m exhausted from all this contemplation... time to watch mindless reality shows and sitcoms the rest of the night:)
Thanks for the info!
Thanks for the explanation!
Thanks Senti, the screen play is just writing itself! All the behind the scenes motives and machinations!
Any ideas why the phase3 trial we all are anxiously awaiting results for continues to show unknown status (trial is more than 2 years past expected completion date without update?)
No, from what I remember there were foundational patents regarding how DC vaccines are made, such that I thought other similar vaccine makers would be beholding to the patents if the patents are vigorously enforced. But hey it has been a long time since patent details were discussed on this board.
A closed system reduces the manual labor, reduces or maybe eliminates the number of super clean rooms and “space suits” and I would think increase quality and yields of vaccine. The density of DC cells is seen to be higher thus more potent vaccine.
That’s a key LP presentation, thanks!
Thank you!
Thanks!
Great info! Thanks much, and thanks to all for the replies !
Correction, increasing quality.
Is this the Corning technology?
Didn’t LP talk about work and progress towards a closed system manufacturing technology that reduced needs for clean rooms and automates the Dcvax production very significantly, thus reducing production costs and quality?
Anyone remember this?
Ring ring...(voice on phone) “Blue clinician likes northwest”
What I remember is that dendreon didn’t have enough margin due to high costs and thus not sustainable company. I didn’t follow closely at the time.
Dr Rago is the real deal. Didn’t appreciate how steeped he is in the cancer genetics field. His NWBO opinions hold more weight with me now. I assumed he was a paid medical expert on Bigger’s investment team but not as closely involved in immunotherapy specifics. You know what they say about “ASSuming. “
Just wanting to understand. I’m among the 10 year longs so I’ve paid my dues and anxious to finally get to unblinded trial results and hopefully dcvaxL approval. I turn 66 this year and hadn’t imagined when I was 55 that it would be another fifth of my life later but here we are inches from the finish line.
This 5 year data keeps coming up however since the site datasets are final and signed off they wouldn’t change. The other data such as IDH and the special analyses will be added and the resulting total trial data will be locked. Wouldn’t adding more of the same data that was already signed and locked be invalidating the sing-offs and require going back to the previous state requiring revaluation and sign offs again?
Blue_skies thanks for the advice!
Yes communications is at the root of good and bad performance in relation to good and bad communications practice, and this applies at every level of an enterprise.